<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04731025</url>
  </required_header>
  <id_info>
    <org_study_id>BREAST-AB-01</org_study_id>
    <secondary_id>2020-002459-40</secondary_id>
    <secondary_id>0058322</secondary_id>
    <nct_id>NCT04731025</nct_id>
  </id_info>
  <brief_title>Local Antibiotics for Breast Implants</brief_title>
  <acronym>BREAST-AB</acronym>
  <official_title>Prophylactic Treatment of Breast Implants With a Solution of Gentamicin, Vancomycin and Cefazolin Antibiotics for Women Undergoing Breast Reconstructive Surgery: a Randomized Controlled Trial (The BREAST-AB Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mikkel Herly</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Herlev and Gentofte Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sydvestjysk Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The BREAST-AB Trial is a multi-center, randomized, double blind, placebo-controlled trial&#xD;
      investigating the efficacy of local application of gentamicin, vancomycin and cefazolin in&#xD;
      decreasing all-cause implant explantation after breast reconstruction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The BREAST-AB Trial will include women undergoing breast reconstruction with implants. The&#xD;
      objective is to determine the efficacy of local antibiotics in decreasing all-cause implant&#xD;
      explantation. Participants will be randomized to local application of placebo or gentamicin,&#xD;
      vancomycin and cefazolin in a saline solution onto the implant and the dissected breast&#xD;
      pocket. All patients undergoing unilateral breast reconstruction will be randomized to the&#xD;
      trial drug or placebo in a ratio of 1:1. All patients undergoing bilateral reconstruction&#xD;
      will be randomized to the trial treatment on one of their breasts and placebo to the&#xD;
      contralateral breast. A total number of 1274 of breasts undergoing breast reconstruction will&#xD;
      be included in the trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 27, 2021</start_date>
  <completion_date type="Anticipated">July 27, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 27, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The trial will be double-blind so that the patients, site investigators and data monitors will be blinded to the allocation. Only the designated nurses and the members of the trial coordinating unit (who provide the randomization number and treatment allocation) are not blinded to the allocation. The unblinded persons will not in any way be part of the treatment, clinical evaluation of outcomes or data assessment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause explantation of the breast implant after the breast reconstruction surgery</measure>
    <time_frame>180 days</time_frame>
    <description>All-cause explantation will be defined as explantation of the implant without insertion of new implant. This will not include replacement of an expander with a permanent implant and replacement of implants due to cosmetic revisions such as asymmetry and implant rotation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to explantation (days)</measure>
    <time_frame>180 days</time_frame>
    <description>Time to explantation will be defined as the amount of days between the breast reconstruction and the implant explantation surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revision surgery with incision of the fibrous capsule after the breast reconstruction surgery (Y/N)</measure>
    <time_frame>180 days</time_frame>
    <description>The breast reconstruction surgery will be defined as the surgery where they received the allocated treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exchange of permanent implant to expander implant after the breast reconstruction surgery (Y/N)</measure>
    <time_frame>180 days</time_frame>
    <description>The breast reconstruction surgery will be defined as the surgery where they received the allocated treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical site infection that leads to antibiotic treatment after the breast reconstruction surgery</measure>
    <time_frame>180 days</time_frame>
    <description>Surgical site infection will be defined according to the CDC classification of surgical site infetion leading to antibiotic treatment with oral or intravenous antibiotics administered after the surgery.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time from the breast reconstruction surgery to discharge (days)</measure>
    <time_frame>180 days</time_frame>
    <description>Time to discharge will be defined as the amount of days between the breast reconstruction and the day of discharge.</description>
  </other_outcome>
  <other_outcome>
    <measure>Re-admission after the breast reconstruction surgery (Y/N)</measure>
    <time_frame>180 days</time_frame>
    <description>The breast reconstruction surgery will be defined as the surgery where the patient received the allocated treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Long term follow-up after 5, 10 and 15 years</measure>
    <time_frame>15 years</time_frame>
    <description>Capsular contracture and the Baker classification grade will be obtained from the National Patient Registry and the patients' medical journals after 5, 10 and 15 years. The BREAST-Q questionnaire will be used to assess patient-reported outcomes. The patients will be contacted and asked to fill out the questionnaire with 5 year-intervals after the surgery.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1003</enrollment>
  <condition>Implant Complication</condition>
  <condition>Implant Infection</condition>
  <condition>Implant Site Infection</condition>
  <condition>Implant Capsular Contracture</condition>
  <condition>Implant Site Pocket Infection</condition>
  <condition>Implant Expulsion</condition>
  <condition>Antibiotic Side Effect</condition>
  <arm_group>
    <arm_group_label>Irrigation of implants with sterile isotonic saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo solution will consist of 500 mL of sterile isotonic (9%) saline contained in a infusion bag.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Irrigation of implants with a triple antibiotic solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The antibiotic solution will contain 1000 mg vancomycin, 80 mg gentamicin and 1000 mg cefazolin in 500 mL sterile isotonic (9%) saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gentamicin, Cefazolin and Vancomycin</intervention_name>
    <description>The antibiotic solution will contain 1000 mg vancomycin, 80 mg gentamicin and 1000 mg cefazolin in a 500 mL isotonic saline solution. The solution will be used to wash the dissected implant pocket and the implant prior to insertion in the implant pocket.</description>
    <arm_group_label>Irrigation of implants with a triple antibiotic solution</arm_group_label>
    <other_name>Hexamycin, Cefazolin &quot;MIP&quot; and Bactocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>500 mL of sterile isotonic (9%) saline. The solution will be used to wash the dissected implant pocket and the implant prior to insertion in the implant pocket.</description>
    <arm_group_label>Irrigation of implants with sterile isotonic saline</arm_group_label>
    <other_name>Natriumklorid Fresenius Kabi 9 mg-ml</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Biologically female&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Scheduled for breast reconstruction with implants or expanders including:&#xD;
&#xD;
               1. Immediate or delayed reconstructions&#xD;
&#xD;
               2. Bilateral or unilateral reconstructions&#xD;
&#xD;
               3. With or without simultaneous flap reconstruction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breast feeding&#xD;
&#xD;
          -  Known allergy towards Vancomycin, Gentamicin and Cefazolin&#xD;
&#xD;
          -  Known anaphylactic reaction towards other beta-lactam antibiotics or aminoglycosides&#xD;
&#xD;
          -  Known allergy towards neomycin&#xD;
&#xD;
          -  Known impaired renal function with GFR &lt; 60 mL/min&#xD;
&#xD;
          -  Participation in investigational drug trials and projects concerning disinfecting&#xD;
             agents in the breast implant cavity&#xD;
&#xD;
          -  Myasthenia Gravis&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mikkel Herly, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Plastic Surgery and Burns Treatment</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mikkel Herly, MD, Ph.D.</last_name>
    <phone>+45 27598919</phone>
    <email>mikkel.herly@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mathilde Hemmingsen, MD</last_name>
    <phone>+45 28568205</phone>
    <email>mathilde.nejrup.hemmingsen@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikkel Herly, MD, Phd</last_name>
      <phone>+45 27598919</phone>
      <email>mikkel.herly@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Mathilde N Hemmingsen, MD</last_name>
      <phone>+45 28568205</phone>
      <email>mathilde.nejrup.hemmingsen@regionh.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>South-West Jutland Hospital</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lena F Carstensen, MD</last_name>
      <phone>+45 20 15 20 19</phone>
      <email>Lena.Felicia.Carstensen@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev and Gentofte Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisbet R Hölmich, MD, DMSc</last_name>
      <phone>+45 27 20 00 14</phone>
      <email>lisbet.rosenkrantz.hoelmich@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Camilla Bille, Phd</last_name>
      <phone>+45 65 41 24 45</phone>
      <email>Camilla.Bille@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zealand University Hospital</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Volker-Jürgen Schmidt, MD</last_name>
      <phone>+45 46 32 3701</phone>
      <email>vosc@regionsjaelland.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vibeke Koudahl, PhD</last_name>
      <phone>+45 79 40 91 65</phone>
      <email>Vibeke.Koudahl@rsyd.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Mikkel Herly</investigator_full_name>
    <investigator_title>MD, Ph.d.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Contracture</mesh_term>
    <mesh_term>Implant Capsular Contracture</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Cefazolin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The protocol will be published prior to unblinding of the results in a methodology article including the statistical analysis plan. The main article will include the primary and secondary outcomes. The tertiary and long-term outcomes will be included in subsequent articles. The manuscripts will be submitted to peer-reviewed international journals and both positive, negative and inconclusive results will be published. The findings of the trial will be shared with participating sites and presented at national and international conferences. The results will be disseminated to the public but will not be shared directly with participating patients.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After the end of the trial, the data will become available (Anticipated july 2024)</ipd_time_frame>
    <ipd_access_criteria>Researchers and other relevant parties can be granted access to selected anonymized data after publication upon request to the principal-sponsor investigator</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

